Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Main Article Content

Kristian Reich
Andrew Blauvelt
Diamant Thaci
Craig Leonardi
Yves Poulin
Daniel Burge
Luke Peterson
Catherine Arendt
Alice B Gottlieb

Keywords

psoriasis, randomized, clinical trial, certolizumab

Abstract

Abstract Not Available

 

Disclosure: Study supported by Dermira.